Medtronic Raises 2027 Outlook Amid Rising Heart Device Demand

Medtronic has revised its fiscal 2027 forecasts upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The company announced this adjustment on Tuesday, reflecting optimism in the medtech sector's growth trajectory.

Financial Forecasts and Strategic Investments

Medtronic has increased the lower end of its adjusted per share profit forecast for fiscal 2027 to $5.94 from $5.90, maintaining the upper limit at $6. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from the prior range of 6.75% to 7.25%.

In a strategic move, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States.

Market Dynamics and Business Performance

CEO Geoff Martha emphasized the broad-based performance across Medtronic's business units and the growing contributions from newer growth platforms as key factors bolstering the company's confidence. Medtronic's finance chief, Thierry Pieton, noted that tariff refunds nearly covered the duties paid during the quarter, although future refunds were not included in the outlook.

Quarterly sales within the cardiovascular segment rose by 19.5% to $3.93 billion, fueled by an impressive 88% growth in its pulsed field ablation portfolio, which addresses irregular heart rhythms. The company reported an adjusted quarterly per share profit of $1.45 on revenues of $9.76 billion, exceeding analysts' expectations of $1.39 per share on $9.55 billion in sales, according to LSEG data.

Focus on Emerging Markets and High Growth Segments

Medtronic's acquisition strategy is focused on high-growth areas within the medtech industry, particularly segments with large patient pools. The company's investments in robotics and cardiovascular technologies align with its priorities. Martha highlighted the low penetration of soft tissue robotic surgery in emerging markets, underlining the potential for growth in these regions.

Medtronic's partnership with Cornerstone Robotics is expected to complement its existing Hugo device, enhancing the company's capabilities in robotic surgery. This approach reflects Medtronic's commitment to expanding its footprint in high-potential segments while navigating the evolving medtech landscape.